First patient recruited for the Actiste® study in the United Kingdom
Brighter AB (publ) (“Brighter” or “The Company'') today announces that in the Actiste® clinical-research – being conducted in partnership with the Northern Care Alliance NHS Foundation Trust in the UK city of Salford – the first patient has been recruited and started to use Actiste®.
The patient will continue to use Actiste® for the next six months to check blood glucose and administer insulin and being an IoT device, Actiste® automatically records this data. Additional clinically relevant information like meals and physical activity in connection to blood glucose measurements and actual injected insulin dose can be tagged on Actiste and can provide an opportunity for the report to be shared with the clinical-research team at Salford Royal Hospital. The patient will also use the Companion app for additional insights about real-life diabetes management.
Later this year the results of the full study – including 35 patients with type 1 diabetes and 35 patients with insulin-treated type 2 diabetes – will be analyzed and study publication will be shared with the diabetes scientific community. The aim is to further verify the potential benefits of Actiste® in managing type 1 and type 2 insulin-treated diabetes and compare it vs the standard of care.
“This is another important milestone for Brighter,” says Brighter CEO Erik Lissner. “It’s very important that we continue to build a body of evidence to support the benefits we see in Actiste® for insulin treated diabetes. This study is contributing to that and will be used as an important tool as we rapidly move forward with the commercialization of Actiste® Diabetes Management as a Service.”
For further information, please contact:
Investor Relations
ir@brighter.se
Certified Adviser
Brighter’s Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se, www.mangold.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.